Synpromics

Sector:
Biotechnology
Exit:
Trade Sale

Synpromics is a Scottish biotech company, and the market leader in gene control therapeutics. Synpromics’ synthetic promoters are designed to better regulate gene activity and precisely control protein production therefore creating better targeted gene therapies. Its technology has wide applications, including potential for the treatment of conditions such as haemophilia, liver and heart disease.

Synpromics was acquired by AskBio, the American pioneer in gene therapeutics delivering an impressive return to investors in 2019.